Gilead’s Q2 Highlights: Long‑Acting Oral HIV PrEP Filing Accepted, EU Expands Trodelvy Label, Phase 3 Lung Cancer Trial Halted

Gilead Sciences (Nasdaq: GILD) posted a flurry of material developments last week that have major implications for its HIV and oncology portfolios.

FDA accepts supplemental NDA for once‑weekly PrEP candidate Yeztugo

In its Q2 earnings release, Gilead disclosed that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application (sNDA) for Yeztugo®, a once‑weekly oral formulation of lenacapavir intended for HIV pre‑exposure prophylaxis (PrEP). The target Prescription Drug User Fee Act (PDUFA) date is set for February 2, 2027. This acceptance marks a meaningful milestone for Gilead’s push into longer‑acting HIV prevention options.

According to Gilead, this regulatory step reflects progress toward diversifying beyond daily PrEP regimens, potentially enhancing adherence and convenience for users. Investors will focus on whether the FDA’s review confirms Yeztugo’s safety and efficacy profile for broader public health impact.

EU widens first‑line label for Trodelvy in breast cancer

Also in Q2, Gilead announced the European Commission has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) as monotherapy in first‑line treatment for unresectable locally advanced or metastatic triple‑negative breast cancer (mTNBC) in patients not eligible for PD‑1/PD‑L1 inhibitors.

Additionally, the European Medicines Agency’s CHMP issued a positive opinion supporting Trodelvy combined with Keytruda® (pembrolizumab) for PD‑L1 high (CPS ≥10) mTNBC in the same setting. These expansions could significantly enlarge Trodelvy’s addressable market in European oncology.

Phase 3 EVOKE‑03 lung cancer trial discontinued

Gilead and partner Merck also disclosed a clinical setback: the external Data Monitoring Committee recommended halting the Phase 3 EVOKE‑03 trial evaluating Trodelvy plus Keytruda in first‑line metastatic non‑small cell lung cancer (mNSCLC) with high PD‑L1 expression (TPS ≥50%). The decision followed interim data showing an insufficient progression‑free survival (PFS) benefit and a low likelihood of overall survival improvement.

This discontinuation underscores the challenges of extending Trodelvy to lung cancer despite promise in breast cancer indications.

Stock context amid developments

As of September 10, 2026, Gilead’s stock closed at $144.81, down 0.18%. While none of these developments directly cited share‑price moves as causal, the FDA acceptance for Yeztugo may support long‑term growth expectations, and the EU regulatory gains could buoy sentiment around oncology prospects. The lung cancer trial halt may temper expectations for further label expansion.

What to watch next

• Yeztugo’s FDA review: February 2, 2027, PDUFA date will determine whether Gilead secures a landmark long‑acting oral PrEP option.
• Commercial uptake in Europe: How quickly Trodelvy’s expanded monotherapy and combination labels advance prescribing in mTNBC.
• Strategic allocation: Gilead balancing focus across HIV prevention innovation versus oncology, especially after the lung cancer trial setback.

Gilead’s recent news reflects strategic momentum toward longer‑acting HIV prophylaxis and bolstered oncology positioning in Europe, even as challenges persist in broader cancer indications.